Repository logo

Cell-surface signatures of immune dysfunction risk-stratify critically ill patients: INFECT study.

Published version

Change log


Conway Morris, Andrew  ORCID logo
Datta, Deepankar 
Shankar-Hari, Manu 
Stephen, Jacqueline 
Weir, Christopher J 


PURPOSE: Cellular immune dysfunctions, which are common in intensive care patients, predict a number of significant complications. In order to effectively target treatments, clinically applicable measures need to be developed to detect dysfunction. The objective was to confirm the ability of cellular markers associated with immune dysfunction to stratify risk of secondary infection in critically ill patients. METHODS: Multi-centre, prospective observational cohort study of critically ill patients in four UK intensive care units. Serial blood samples were taken, and three cell surface markers associated with immune cell dysfunction [neutrophil CD88, monocyte human leucocyte antigen-DR (HLA-DR) and percentage of regulatory T cells (Tregs)] were assayed on-site using standardized flow cytometric measures. Patients were followed up for the development of secondary infections. RESULTS: A total of 148 patients were recruited, with data available from 138. Reduced neutrophil CD88, reduced monocyte HLA-DR and elevated proportions of Tregs were all associated with subsequent development of infection with odds ratios (95% CI) of 2.18 (1.00-4.74), 3.44 (1.58-7.47) and 2.41 (1.14-5.11), respectively. Burden of immune dysfunction predicted a progressive increase in risk of infection, from 14% for patients with no dysfunction to 59% for patients with dysfunction of all three markers. The tests failed to risk stratify patients shortly after ICU admission but were effective between days 3 and 9. CONCLUSIONS: This study confirms our previous findings that three cell surface markers can predict risk of subsequent secondary infection, demonstrates the feasibility of standardized multisite flow cytometry and presents a tool which can be used to target future immunomodulatory therapies. TRIAL REGISTRATION: The study was registered with (NCT02186522).



Cross infection, Immunoparesis, Immunophenotyping, Monocytes, Neutrophils, T-lymphocytes, regulatory, Aged, Critical Illness, Female, HLA-DR Antigens, Humans, Immune System Diseases, Intensive Care Units, Male, Middle Aged, Predictive Value of Tests, Prospective Studies, Receptor, Anaphylatoxin C5a, Risk Assessment, T-Lymphocytes, Regulatory

Journal Title

Intensive Care Med

Conference Name

Journal ISSN


Volume Title



Springer Science and Business Media LLC
Wellcome Trust (205214/Z/16/Z)
The study was funded by Innovate UK (Sepsis 2: 101193), BD Biosciences and the National Institute for Academic Anaesthesia. Dr Conway Morris is supported by a Clinical Research Career Development Fellowship from the Wellcome Trust (WT 2055214/Z/16/Z). Dr Shankar-Hari is supported by the National Institute for Health Research Clinician Scientist Award (CS-2016-16- 011).